We are very proud to announce that Aniling has reached the CE Mark for our first product, GEUS-CLL, a first-in-class IVD medical device to support the diagnosis, prognosis, treatment selection …
Aniling owns the GEUS technology, which unifies genetic and epigenetic sequencing and provides end-to-end solutions for the right treatment decisions in oncology. Based on GEUS, Aniling is developing a set of products for cancer diagnostic.
The first Aniling product is the most comprehensive Chronic Lymphocytic Leukemia Next Generation Sequencing diagnostics panel. The GEUS-CLL delivers accurate staging and treatment decisions. Aniling S.L. provides the GEUS-CLL diagnostic test as a service to other laboratories and hospitals.
Liquid biopsy tests provide access to tumor DNA in a minimally invasive way, offering great potential in oncology applications, including precision medicine, early cancer diagnosis and disease’s follow-up and monitoring. At Aniling, we have developed a new product, GEUS-LB, targeting …